Novel applications of TRPV4 agonist GSK1016790A
A GSK1016790A, agonist technology, applied in the field of medicine, can solve problems such as diabetes cognitive function decline, achieve the effect of increasing new object recognition ability, high clinical application value and development prospect, and increasing preference
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0025] Example 1: Novel Object Recognition (NOR) Experimental Investigation of the Effect of TRPV4 Agonist GSK1016790A on Novel Object Recognition in STZ-Induced Cognitive Impairment Model Mice
[0026] Animals: 24 male ICR mice, 3 months old, weighing about 30-40 g. Animals were kept at room temperature (22±2)°C, humidity (45%-65%) and light and dark (12h:12h) environment, free to eat and drink.
[0027] Animal grouping and treatment: mice were divided into 3 groups according to the random number table method: vehicle control group (DMSO+NS, n=8), diabetic cognitive impairment model group (DMSO+STZ, n=8), GSK1016790A group (GSK +STZ, n=8), the mice were given intraperitoneal injection of streptozotocin (STZ, 55mg / kg) after daily fasting for 6h (8:30-14:30) for five consecutive days, to establish diabetic cognitive impairment Model. Mice in the DMSO+NS group were injected with an equal volume of normal saline in the same way. GSK1016790A (0.125mg / kg) or its vehicle DMSO was...
Embodiment 2
[0031] Example 2: Investigation of the effect of TRPV4 agonist GSK1016790A on novel location recognition in STZ-induced cognitive impairment model mice
[0032] Animals: 24 male ICR mice, 3 months old, weighing about 30-40 g. Animals were kept at room temperature (22±2)°C, humidity (45%-65%) and light and dark (12h:12h) environment, free to eat and drink.
[0033] Animal grouping and treatment: Mice were divided into 3 groups according to the random number table method: vehicle control group (DMSO+ NS, n=8), diabetic cognitive impairment model group (DMSO+STZ, n=8), GSK1016790A group (GSK+ STZ, n=8), the mice were fasted for 6 hours (8:30-14:30) and given intraperitoneal injection of streptozotocin (STZ, 55mg / kg) for five consecutive days to establish a diabetic cognitive impairment model . Mice in the DMSO+NS group were injected with an equal volume of normal saline in the same way. GSK1016790A (0.125mg / kg) or its vehicle DMSO was injected intraperitoneally continuously fo...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com